Nektar Therapeutics Balance Sheet - Annual (NASDAQ:NKTR)

Add to My Stocks
$22.53 $0.36 (1.57%) NKTR stock closing price Mar 23, 2017 (Closing)

A thorough fundamental analysis involves using data from Nektar Therapeutics balance sheet, apart from other financial statements, to value the business. A balance sheet can help evaluate the financial performance of a company. Ratios like return on total assets and current ratio, which also uses cash on hand can be used to measure the operating efficiency of a firm, and can be used to conduct a more accurate Nektar Therapeutics stock analysis. Good quarterly results indicate a company's strong financial performance. Its important to check all financial statements including the balance sheet. Nektar Therapeutics revenue was $230.78M and Nektar Therapeutics operating cash flow was $-73.08M for 2015. The balance sheet shows total liabilities of $495.63M and shareholders equity of $6.42M. View latest and last 10 year balance sheet data to check Nektar Therapeutics financial performance..

show more
Annual
Quarterly
View Previous Years
View Next Years
Fiscal year is Jan - Dec. 2015 2014 2013 2012 2011 2010 2009 2008 2007
Cash55.57M37.36M39.06M25.43M15.31M17.75M49.59M155.58M76.29M
Marketable Securities253.37M225.45M197.95M251.75M225.85M298.17M346.61M223.41M406.06M
Receivables19.94M3.6M2.22M5.8M4.93M25.1M4.8M11.16M21.63M
Inventory11.34M12.95M13.45M18.26M12.65M7.26M6.47M9.31M12.18M
Raw Materials3.23M2.2M3.94M7.48M9.75M6.1M5.93M6.96M-
Work In Progress6.08M5.18M6.14M6.66M1.21M--1.74M-
Finished Goods2.02M5.56M3.35M4.11M1.68M1.16M0.53M0.61M-
Notes Receivable---------
Other Current Assets9.81M8.81M5.17M13.36M17.94M5.67M6.18M6.74M7.1M
Nektar Therapeutics Total Current Assets
350.05M288.2M257.88M314.63M276.7M353.97M413.66M406.22M523.28M
Property Plant & Equipment174.04M164.17M151.12M144.88M140.81M143.76M132.66M117.08M-
Accumulated Depreciation102.71M93.8M84.14M72.66M62.23M53.99M54.4M43.5M-
Nektar Therapeutics Net Property Plant & Equipment
71.33M70.36M66.97M72.21M78.57M89.77M78.26M73.57M114.42M
Investment & Advances----173.76M----
Other Non-Current Assets---------
Deferred Charges---------
Intangibles76.5M76.5M76.5M76.5M76.5M76.5M76.5M76.5M81.11M
Deposits & Other Assets4.17M6.55M33.17M34.44M0.99M0.97M7.08M4.23M6.28M
Nektar Therapeutics Total Assets
502.06M441.62M434.52M497.79M606.55M521.22M575.51M560.53M725.1M
Notes Payable---------
Accounts Payable2.36M2.7M9.11M2.86M3.01M7.19M3.06M13.83M3.58M
Current Portion Long-Term Debt----214.95M----
Current Portion Capital Leases4.75M4.51M------2.33M
Accrued Expenses22.57M26.79M44.31M41.36M31.42M29.93M28.57M39.11M70.2M
Income Taxes Payable---------
Other Current Liabilities31.55M30.04M44.78M34.31M26.12M26.97M121.37M15.42M21.96M
Nektar Therapeutics Total Current Liabilities
61.24M64.04M98.22M78.53M275.53M64.1M153.01M68.37M98.09M
Mortgages---------
Deferred Taxes/Income62.42M76.91M82.38M98.95M111.46M128.91M81.83M61.46M61.34M
Convertible Debt-----214.95M214.95M214.95M315M
Long-Term Debt242.11M125M125M125M-----
Non-Current Capital Leases1.07M4.13M8.04M11.6M14.58M17.01M18.8M20.34M21.63M
Other Long-Term Liabilities128.77M135.19M210.77M136.67M7.15M5.57M4.54M5.23M14.59M
Nektar Therapeutics Total Liabilities
495.63M405.28M524.43M450.77M408.73M430.56M473.15M370.38M510.66M
Minority Interest---------
Preferred Stock---------
Common Stock Net0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M
Capital Surplus1.88B1.82B1.64B1.62B1.6B1.35B1.33B1.31B1.3B
Retained Earnings-1.87B-1.79B-1.73B-1.57B-1.4B-1.26B-1.23B-1.12B-1.09B
Treasury Stock---------
Other Liabilities-2.17M-1.56M-1.18M-0.35M-1.1M0.96M1.02M1.43M1.64M
Nektar Therapeutics Shareholders Equity
6.42M36.33M-89.9M47.01M197.81M90.66M102.36M190.15M214.43M
Nektar Therapeutics Total Liabilities & Shareholders Equity
502.06M441.62M434.52M497.79M606.55M521.22M575.51M560.53M725.1M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years
Get Balance sheet for another ticker

1:22
NKTR
Most investors just check the Nektar Therapeutics stock price, and Nektar Therapeutics historical stock prices before investing. While share price is an important factor, one should also look at financials and valuation metrics like the Nektar Therapeutics PE ratio chart. Below is a brief explanation of common balance sheet terms:
  • Assets: NKTR total assets, which was at $502.06M for 2015 is a balance sheet item representing value of what Nektar Therapeutics owns. Assets are brought to aid a firms operations, or to increase its economic value. It must be noted that tech stocks may not have a lot of assets, as the value for these companies is often derived from future earning potential.
  • Liabilities: The total liabilities of Nektar Therapeutics for 2015 total to $495.63M. Liabilities for a company like Nektar Therapeutics include bank loans, services which have been availed for which a settlement in the form of cash/ asset transfer needs to be done in future etc. A firm takes on such obligations to grow its business which in turn will generate future economic benefits for its business.
.

Nektar Therapeutics Balance Sheet - Key Ratios

Current ratio
3.7
Asset Turnover
ratio
0.33
receivables turnover
ratio
8
PB ratio (
price to book ratio
)
-1309.8860